drugset
drugset / Trial / NCT02260076

Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects

NCT02260076 ↗

Phase 1 Completed 64 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the safety and tolerance of 5 mL to 20 mL PEG 400 in multiple rising doses

Timeline

Start
2001-09
Primary completion
2002-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject PEG-400 Unknown 5 ml Oral
Subject PEG-400 Unknown 10 ml Oral
Subject PEG-400 Unknown 15 ml Oral
Subject PEG-400 Unknown 20 ml Oral

Indications

No indication recorded.